Keytruda's Urothelial Cancer Claim Goes From Accelerated To Full Approval, With More Limited Scope

 
• By Sue Sutter
  
Narrow opening
FDA has narrowed the first-line urothelial carcinoma population for Keytruda. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

More from Product Reviews